Pamrevlumab did not meet its primary endpoint for non-ambulatory patients with Duchenne Muscular Dystrophy: the LELANTOS-1 trial
Anne M. Connolly(Washington University in St. Louis), Ewa Carrier(FibroGen (United States)), John F. Brandsema, Xiaotang Cai(Sichuan University), Olga V. Gambetti(FibroGen (United States)), Brenda Wong(Cincinnati Children's Hospital Medical Center), Yann Péréon(European Organisation for Rare Diseases), Stefano C. Previtali(Vita-Salute San Raffaele University), Steven Wang(FibroGen (United States)), Cuixia Tian(Cincinnati Children's Hospital Medical Center), H. Phan(Rare Disease Therapeutics (United States)), Stanley F. Nelson(University of California, Los Angeles), Eugenio Mercuri(Università Cattolica del Sacro Cuore), Silvana De Lucia(Sorbonne Université)
Cited by 3
Related Papers
Mitochondrial neurogastrointestinal encephalomyopathy: An autosomal recessive disorder due to thymidine phosphorylase mutations
|Annals of Neurology|2000|343
Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort
|Human Mutation|2009|314
Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne’s Muscular Dystrophy
|New England Journal of Medicine|2023|302
Functional changes in Duchenne muscular dystrophy
|Neurology|2011|178
Congenital Titinopathy: Comprehensive characterization and pathogenic insights
|Annals of Neurology|2018|166